A Phase 3b/4,Multi-center, Double-blind, Randomized, Parallel Group Study Of Tofacitinib (Cp-690,550) In Subjects With Ulcerative Colitis In Stable Remission
Phase of Trial: Phase III/IV
Latest Information Update: 10 Aug 2018
At a glance
- Drugs Tofacitinib (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms RIVETING STUDY
- Sponsors Pfizer
- 18 Apr 2018 This study has been discontinued in Austria.
- 06 Mar 2018 Planned primary completion date changed from 9 Nov 2018 to 10 Nov 2018.
- 19 Feb 2018 Planned End Date changed from 16 Dec 2021 to 14 Dec 2019.